منابع مشابه
The all-units and incremental discount cases
This article studies the classical reorder quantity, order point (Q, r) continuous review stochastic inventory model with Poisson arrivals and a fixed lead time. This model has been extensively studied in the literature and its use in practice is widespread. This work extends previous research in this area by providing efficient algorithms for the computation of the optimal (Q∗, r∗) values when...
متن کاملDiscount Sensitivity – Are We All Equal?
The high adoption of smart mobile devices among consumers is an opportunity for ecommerce retailers to increase their sales by recommending consumers with real time, personalized coupons which take into account the specific contextual situation of the consumer [5]. While context-aware recommender systems (CARS) have been widely analyzed [1,2] personalized pricing or discount optimization in rec...
متن کاملCurcumin: The All in One Solution Curcumin: The All in One Solution
Curcumin is also a potent antioxidant, able to neutralize unstable, reactive free radicals. Free radicals are molecules with a missing electron that stabilize themselves by “stealing” electrons from neighboring molecules, creating another free radical Indian Solid Gold Dried and powdered turmeric has been used in India as both a spice and a medicine for centuries. In addition to flavoring food,...
متن کاملCurcumin: The All in One Solution Curcumin: The All in One Solution
10260_0113_TTN080 Curcumin is also a potent antioxidant, able to neutralize unstable, reactive free radicals. Free radicals are molecules with a missing electron that stabilize themselves by “stealing” electrons from neighboring molecules, creating another free radical in the process. This chain reaction of free radical formation is known as a free radical cascade, and it can result in cellular...
متن کاملOpen Clinical Trial Data for All? A View from Regulators
In this issue of PLoS Medicine, Doshi and colleagues argue that the full clinical trial reports of authorized drugs should be made publicly available to enable independent re-analysis of drugs’ benefits and risks [1]. We offer comments on their call for openness from a European Union drug regulatory perspective. For the purpose of this discussion, we consider ‘‘clinical study reports’’ to compr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 2017
ISSN: 0028-0836,1476-4687
DOI: 10.1038/543040c